What does Mounjaro do, and why does it work differently from other treatments?

The clinical results that put tirzepatide on the map

SURMOUNT-1 enrolled 2,539 adults with obesity who did not have type 2 diabetes. After 72 weeks, participants using the highest 15mg dose lost roughly 20–21% of their starting body weight on average. For context, that's more than any single-receptor GLP-1 medicine had achieved in equivalent trials at that point. In a later head-to-head study (SURMOUNT-5) tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in people living with obesity. NICE reviewed this evidence when it recommended tirzepatide in December 2024 under technology appraisal TA1026. None of this means everyone loses the same amount; results in trials reflect averages across thousands of participants, and individual outcomes depend on starting weight, adherence, diet, activity and other health factors. But the size and consistency of the trial data gave regulators and clinicians something they hadn't seen from earlier treatments.

It's also worth knowing what Mounjaro doesn't do on its own. The trials ran alongside a reduced-calorie diet and increased physical activity. The medicine lowers the biological drive to eat; it works most effectively when you build on that opening rather than treating it as the whole solution. Many people find this less effortful than it sounds (appetite suppression tends to make the lifestyle adjustments feel more manageable) but the combination matters.

What's actually happening inside your body on Mounjaro

Tirzepatide is described as a dual GIP and GLP-1 receptor agonist. Both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are hormones your gut releases naturally after eating. They signal to the pancreas, the brain and the digestive tract in ways that regulate insulin, appetite and how quickly the stomach empties. Mounjaro mimics both signals at once, which appears to produce a stronger combined effect than activating either pathway alone, hence the trial results that sit above single-agonist medicines. A more detailed explanation of the receptor mechanism walks through each pathway individually if you want to go deeper.

Slowed gastric emptying is part of why nausea is one of the more commonly reported side effects, particularly in the early weeks. Food staying in the stomach longer can feel uncomfortable until your body adjusts. This is also why tirzepatide treatment begins at 2.5mg, a dose designed to let your digestive system adapt, rather than to produce immediate weight loss. The full tirzepatide overview page covers the licensed dose schedule and what each stage is for.

What Mounjaro is licensed to treat in the UK

In the UK, Mounjaro holds two licences. The first is for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or prediabetes. The second licence covers type 2 diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. It is not licensed for use in people under 18, and it is not recommended during pregnancy, whilst breastfeeding, or when trying to conceive. Conditions including a history of medullary thyroid carcinoma or pancreatitis require particular attention from a prescriber. The NHS provides a clear summary of who tirzepatide is and isn't suitable for, which is worth reading alongside any consultation.

BMI alone doesn't determine approval. A prescriber looks at the whole picture: your health history, current medicines, any contraindications and what you're hoping to achieve. That clinical review matters because tirzepatide is a powerful medicine with a real side-effect profile, not a supplement. If you're curious how the private route to treatment works, the Mounjaro overview page sets out what to expect step by step.

Side effects: what the evidence shows and when to get help

The most commonly reported side effects in SURMOUNT-1 were gastrointestinal: nausea, diarrhoea, vomiting, constipation and indigestion. Most were mild to moderate in severity and tended to be most noticeable after starting treatment or after a dose increase, settling as the body adjusted. Injection-site reactions, headache, dizziness and fatigue were also reported. There's more practical guidance on managing day-to-day life on Mounjaro (including eating patterns that tend to reduce nausea) if that's where your questions are heading.

Two side effects merit specific mention. Acute pancreatitis is a known but infrequent risk; the MHRA highlighted it in a safety communication in early 2026. If you develop severe stomach pain that radiates to the back, with or without vomiting, seek medical attention the same day rather than waiting for your next appointment. Gallbladder problems have also been reported at higher rates than in placebo groups in trials. Neither of these is common, but both are reasons why ongoing clinical oversight (not just a one-off prescription) is part of responsible treatment. Side effects and suspected reactions can be reported directly through the MHRA Yellow Card scheme. If you'd also like to know what to avoid while using Mounjaro, that page covers common interactions and habits that can affect how well treatment goes.

One thing people tell us they weren't expecting: once the initial adjustment period passes, many find the medicine quieter than they imagined. The appetite change can feel subtle rather than dramatic. That's not a failure of the medicine, it's often a sign that the dose is calibrated correctly and doing its job without overwhelming your system.

If you want to understand how private treatment is priced before deciding whether to proceed, the Mounjaro price comparison page sets out what the UK market looks like and what a legitimate price actually includes. When you're ready to speak to a prescriber, check your eligibility through a free consultation.